Impact of a device that continuously measures glucose levels and patient education using written information and a consultation with a physician specialising on diabetes on patients with prediabetes identified by point-of-care tests in community pharmacies

Impact of continuous glucose monitoring and patient education on patients with prediabetes identified by point-of- care tests in community pharmacies

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN74492936

Enrollment

100

Registered

2026-04-10

Start date

2026-04-13

Completion date

Unknown

Last updated

2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes defined as having an HbA1c of =5.7% and =6.4% Nutritional, Metabolic, Endocrine

Interventions

Randomization will be conducted with a web-based program available at https://www.meduniwien.ac.at/randomizer using permuted blocks of variable size. A continuous glucose measurement sensor will be

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. =18 years of age 2. Screening is recommended by the Austrian Diabetes Society: >45 years of age, or >35 years of age with =1 risk factor: 2.1. First-degree relatives with diabetes 2.2. BMI =25 kg/m² (or =23 kg/m² for people with Asian descent) 2.3. Metabolic syndrome 2.4. Arterial hypertension 2.5. Dyslipidemia 2.6. Steatosis hepatis 2.7. History of gestational diabetes 2.8. Polycystic ovary syndrome For Interventional Trial: 1. HbA1c% of =5.7% and =6.4% 2. Willingness to participate in the study and comply with the study’s requirements: 2.1. To wear a continuous glucose monitoring sensor for the projected time (maximum 14 days) 2.2. To share quantified glucose concentrations with the study team 2.3. To participate in all planned visits within the planned time-frame 2.4. To document their food intake during CGM periods (e.g., via taking photos or notes) 2.5. To have a smartphone

Exclusion criteria

Exclusion criteria: For Screening Part: 1. Prior diagnosis with prediabetes or diabetes 2. Treatment with antidiabetic drugs For Interventional Trial: 1. Inability to comply with the trial’s requirements 2. Skin conditions or prohibiting the use of a glucose monitor (wounds, eczema, dermatitis, infections, sunburns, etc) 3. Allergies or intolerances against the sensor or its materials/constituents, e.g., allergies against acrylic adhesive, isobornyl acrylate (IBOA), polyurethane, epoxy resins, plaster and tapes 4. Pregnancy or breastfeeding 5. Planned magnetic resonance imaging or computed tomography scans during the times when the CGM should be worn 6. Planned treatment with diathermy 7. Pregnancy – females with an ongoing pregnancy with prediabetes must not participate in the trial 8. Intake of methyldopa or high doses of Vitamin C (>500 mg/day or intravenous Vitamin C) 9. Intake of systemic corticosteroids

Countries

Austria

Contacts

Public ContactChristian Schoergenhofer

christian.schoergenhofer@meduniwien.ac.at+43 (0)14040029810

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 30, 2026